Navigation Links
Roche, InterMune and Pharmasset Announce Initiation of INFORM-1, the First Dual-Combination Clinical Trial with Oral Antivirals in Hepatitis C
Date:11/10/2008

PRINCETON, N.J., Nov. 10 /PRNewswire-FirstCall/ -- Pharmasset, Inc. (Nasdaq: VRUS), Roche (SWX: ROG) and InterMune, Inc. (Nasdaq: ITMN) today announced that the first patients have been dosed in an innovative clinical trial in patients chronically infected with the hepatitis C virus (HCV). The trial (run in centers in Australia and New Zealand) is the first to investigate the combination of two oral antiviral molecules in the absence of interferon.

The initial study will evaluate the safety and combined antiviral activity of R7227 (ITMN-191), a protease inhibitor, and R7128, a polymerase inhibitor, in 14 days of combination therapy in treatment-naive patients infected with HCV genotype 1.

This direct antiviral combination study represents an important first step in evaluating the therapeutic potential of an all-oral, interferon-free combination treatment for HCV. Roche is uniquely positioned to develop all-oral combination studies in HCV through its collaborations with InterMune and Pharmasset, which provide access to both protease and polymerase inhibitors, respectively.

With InterMune, Roche is developing R7227, an HCV protease inhibitor compound to be used in combination with PEGASYS(R) (peginterferon alfa-2a) and COPEGUS(R) (ribavirin), the current standard of care (SOC). Concurrently with Pharmasset, Roche is developing R7128, an HCV RNA polymerase inhibitor, also for therapy in combination with PEGASYS(R) and COPEGUS(R). Both of these molecules have successfully completed Phase 1 monotherapy
'/>"/>

SOURCE Pharmasset, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. InterMune Announces Start of 14-Day Triple Combination Study of ITMN-191 in Patients With Chronic Hepatitis C
2. InterMune Announces Receipt of Fast Track Designation for Pirfenidone From FDA
3. InterMune Announces Progress on Pirfenidone in IPF
4. InterMune Provides Additional Information on ITMN-191 (R7227) MAD Study Results
5. InterMune Announces Top-Line Results of Phase 1b Trial of ITMN-191 (R7227) and Provides Program Update
6. InterMune Announces Start of Phase 1b Trial of ITMN-191
7. InterMune Announces Approval of Clinical Trial Authorization for Phase 1b Trial of ITMN-191
8. Richard E.T. Smith, Ph.D. Joins Pharmasset as Vice President of Investor Relations and Corporate Communications
9. Pharmasset to Present at the UBS Global Life Sciences Conference on Wednesday, September 24th
10. Pharmasset Reports Financial Results for Quarter Ended June 30, 2008
11. Pharmasset Reports Preliminary Results of a 4-week Combination Study of R7128 for the Treatment of Chronic Hepatitis C
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... -- IGI Laboratories, Inc. (NYSE MKT: IG; "IGI" or the ... $125 million aggregate principal amount of 3.75% Convertible Senior ... and sold only to qualified institutional buyers pursuant to ... amended (the "Securities Act"). The Notes bear ... payable semiannually in arrears on June 15 and December ...
(Date:12/17/2014)... RALEIGH, N.C. , Dec. 17, ... (CTMC), and Integrated Clinical Trial Services, LLC (ICTS), ... for clinical trials announce that they have formed ... Services (i-CTMS). i-CTMS will provide a broad range ... biotechnology and medical device companies. i-CTMS ...
(Date:12/15/2014)... , December 15, 2014 ... Am 19. und 20. Februar sind ... Aegate SAFE MEDICINE ECOSYSTEM PARTNER PROGRAMM ™ ... zu besuchen. Diese Tagung soll ... die Möglichkeit geben, die neue profitablen Unternehmensdienstleistungen, ...
Breaking Medicine Technology:IGI Laboratories Announces Closing of $125 Million of 3.75% Convertible Senior Notes Due 2019 2IGI Laboratories Announces Closing of $125 Million of 3.75% Convertible Senior Notes Due 2019 3IGI Laboratories Announces Closing of $125 Million of 3.75% Convertible Senior Notes Due 2019 4Integrated Clinical Trial Services and Clinical Trial Marketing Communications Form Joint Venture 2Integrated Clinical Trial Services and Clinical Trial Marketing Communications Form Joint Venture 3Symposium über Aegates Ecosystem-Partner-Programm für sichere Medikamente vom 19. - 20. Februar 2015 in Amsterdam 2
... COLUMBUS, Ohio, Jan. 8 IntelligentMDx a developer and ... that verification studies of the IntelligentMDx BK Viral ... the Limit of Detection, linearity, specificity and reproducibility ... were determined. The data obtain agreed with internally ...
... have identified mutations in a gene that predict a high ... Although the researchers caution that further research is needed to ... or IKAROS, lead to leukemia relapse, the findings ... to assess the risk of treatment failure. By using a ...
Cached Medicine Technology:Verification Studies of IntelligentMDx's Proprietary Molecular Diagnostic Assay Process Have Been Completed 2Verification Studies of IntelligentMDx's Proprietary Molecular Diagnostic Assay Process Have Been Completed 3Gene Abnormality Found to Predict Childhood Leukemia Relapse 2Gene Abnormality Found to Predict Childhood Leukemia Relapse 3Gene Abnormality Found to Predict Childhood Leukemia Relapse 4Gene Abnormality Found to Predict Childhood Leukemia Relapse 5Gene Abnormality Found to Predict Childhood Leukemia Relapse 6
(Date:12/19/2014)... 2014 (HealthDay News) -- Traveling through the same U.S. ... to three others within a four-hour time span, illustrating ... report shows. "The exposures in this report were ... an international terminal, highlighting the fact that measles is ... an infectious disease specialist at the U.S. Centers for ...
(Date:12/17/2014)... (PRWEB) December 17, 2014 While countless companies ... do not realize the potential dangers of their purchase. Not ... prescription from a qualified doctor, but patients who buy hCG ... point that there is actually no real hCG present. Illegal ... where there are no safety standards and may contain unknown ...
(Date:12/17/2014)... Providence, RI (PRWEB) December 17, 2014 ... nationally recognize private practices that have made outstanding ... and in support and progression of private practice ... the American Physical Therapy Association. , On behalf ... DPT, OCS, owner and CEO of Performance accepted ...
(Date:12/17/2014)... WI (PRWEB) December 17, 2014 In ... Administrators and its Argus Claim Review division have ... of the most common ways savings are achieved on ... (TPA) attributes millions of dollars in savings to Argus ... in 2013. , As explained by Tom Doney, Cypress ...
(Date:12/17/2014)... Project Veritas is releasing a video ... MIT economist and Obamacare architect Jonathan Gruber to public ... the interview, which is being distributed on YouTube. , ... mislabeling in the Affordable Care Act in order to ... billion dollar per year tax grab. , “President Obama ...
Breaking Medicine News(10 mins):Health News:Arriving Now at Gate 42: Measles 2Health News:Arriving Now at Gate 42: Measles 3Health News:Diet Doc Reveals the Real Dangers for Those who Buy hCG Online 2Health News:Diet Doc Reveals the Real Dangers for Those who Buy hCG Online 3Health News:Performance Physical Therapy Awarded with Jayne L. Snyder Private Practice of the Year 2014 2Health News:Out-of-Network & Medical Necessity Reviews among Top Ways TPA Identifies Significant Medical Claim Savings 2Health News:Project Veritas: James O’Keefe Interviews the Man Who Discovered Jonathan Gruber Videos 2
... Calif., April 24 Ten thousand homecare workers won a ... financial reasoning behind proposed wage cuts "perverse" and ordered the ... immediate $1.10 an hour over six months to a smaller ... Board of Supervisors passed a new proposal last week to ...
... fibrillation ups long-term risk of dying, researchers report , , ... the heartbeat abnormality called atrial fibrillation after heart bypass ... new study finds. , The report sounds a warning ... been a matter of major concern, said Giovanni Filardo, ...
... American Cancer Society, the largest non-government, not-for-profit funding source ... 143 national research and training grants totaling more than ... for 2009. The grants go into effect beginning July ... American Cancer Society,s extramural research grants program has devoted ...
... (April 23, 2009) Talecris Biotherapeutics, Inc. today ... life results from the largest clinical trial ever ... (CIDP) in the April 14, 2009 issue of ... long-term treatment with Gamunex (Immune Globulin Intravenous (Human), ...
... Percent for PUR Faucet Filters and More Than 96 ... Associated Press issued a new report on April ... Pharmaceuticals have now been detected in the drinking water ... have found no evidence of adverse health effects by ...
... Pledge to Protect Children From Malaria, Killer of 3,000 ... UNICEF today announced that it will be the ... for the provision of insecticide-treated nets (ITNs) meant to ... Malaria Day, April 25.The gift comes as the result ...
Cached Medicine News:Health News:Arbitrator Calls Fresno Board of Supervisors' Planned Cuts to Homecare Workers 'Perverse'; Orders Cuts Reduced 2Health News:Abnormal Heartbeat After Bypass a Bad Sign 2Health News:American Cancer Society awards 143 research grants to investigators at 83 institutions nationwide 2Health News:American Cancer Society awards 143 research grants to investigators at 83 institutions nationwide 3Health News:American Cancer Society awards 143 research grants to investigators at 83 institutions nationwide 4Health News:American Cancer Society awards 143 research grants to investigators at 83 institutions nationwide 5Health News:American Cancer Society awards 143 research grants to investigators at 83 institutions nationwide 6Health News:Landmark study demonstrates Gamunex improves health-related quality of life in patients with CIDP 2Health News:Landmark study demonstrates Gamunex improves health-related quality of life in patients with CIDP 3Health News:PUR Water Filtration Systems Can Reduce Trace Levels of Pharmaceuticals Found in Some U.S. Tap Water 2Health News:PUR Water Filtration Systems Can Reduce Trace Levels of Pharmaceuticals Found in Some U.S. Tap Water 3Health News:Children Emerge as Winners in Twitter Challenge Between Ashton Kutcher and CNN 2Health News:Children Emerge as Winners in Twitter Challenge Between Ashton Kutcher and CNN 3
MPatch® is a topical adhesive wound dressing for the local management and control of bleeding from vascular access sites and percutaneous catheters....
The MYO-VAD is a novel cardiac support system with unique, life-saving features....
O-arm combines the best features of a traditional c-arm with an intra-operative 3D scannerfor unparalleled surgical imaging....
... full picture ,CardioPAL SAVI is the ... cial Intelligence, with a smart algorithm running ... on each device. The Diogenes algorithm continuously ... rate, rhythm, morphology, and p-wave abnormalities ...
Medicine Products: